Portal de Periódicos da CAPES

Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi

2016; Mary Ann Liebert, Inc.; Volume: 32; Issue: 8 Linguagem: Inglês

10.1089/aid.2015.0366

1931-8405

Sandro Mancinelli, Clementina Maria Galluzzo, Mauro Andreotti, Giuseppe Liotta, Haswel Jere, Jean‐Baptiste Sagno, Roberta Amici, Maria Franca Pirillo, P Scarcella, Maria Cristina Marazzi, Stefano Vella, Leonardo Palombi, Marina Giuliano,

HIV Research and Treatment

The objective of this study was to determine the virological response and the possible emergence of drug resistance at 1 and 2 years postpartum in HIV-positive pregnant women enrolled under the Option B approach and meeting the criteria for treatment. In the study, women with baseline CD4+ 50 copies/ml. Baseline resistance mutations were assessed in the entire cohort. A total of 107 women were studied. At baseline, resistance mutations were seen in 6.6% of the women. At 12 months, 26.7% of the women had >50 copies/ml and among them 12.9% had virological failure (HIV-RNA >1,000 copies/ml). At 24 months, detectable HIV-RNA was seen in 28.3% of the women and virological failure in 10.1% of the women. Resistance mutations (mainly non-nucleoside reverse transcriptase inhibitors mutations) were seen in 40% of the women with detectable HIV-RNA. Baseline mutations did not correlate with virological failure or the emergence of resistance at later time points. Virological failure 2 years postpartum and emergence of resistance were rare in this cohort of HIV-infected women. These findings are reassuring in the light of the new strategies for the prevention of mother-to-child HIV transmission, recommending life-long antiretroviral therapy administration.